Which country is the drug Upadacitinib produced in?

Upadacitinib (Upadacitinib) is an innovative oral JAK1 selective inhibitor developed by the US pharmaceutical giant AbbVie. Its original drug is produced in AbbVie Deutschland GmbH & Co. KG in Germany. This production base is AbbVie's important R&D and manufacturing center in Europe and is responsible for the preparation of a number of global best-selling drugs, including the export of upadatinib raw materials and preparations. The drug was first approved for marketing by the US FDA in 2019, and subsequently entered the European, Japanese, Australian and Chinese markets. A unified quality and production supervision system has been established globally to ensure the purity and efficacy of the drug.

As a global biopharmaceutical company, AbbVie has long been focused on innovative research in the fields of immunology, oncology and neuroscience. Upadatinib is one of its core products in the field of immune diseases and is positioned as a drug for precise regulation of the JAK pathway. The drug selectively inhibits JAK1 and tries to avoid affecting JAK2 and JAK3, thereby suppressing the inflammatory response while reducing the risk of some side effects. AbbVie adopts a highly automated pharmaceutical preparation process and a strict quality traceability system at its German production base. Each batch of upadatinib must pass European Medicines Agency (EMA) standard certification before leaving the factory to ensure compliance with international GMP regulations.

The global production layout of upadacitinib reflects AbbVie’s high standards and high reliability in the international pharmaceutical industry chain. Its export version will be adapted to different markets in terms of packaging, labeling and drug specifications. For example, the dosages of Rinvoq capsules sold in Europe are mainly 15 mg, 30 mg, and 45 mg, while the versions introduced in the Chinese market are mostly sold in tablet form. As it is included in some medical insurance negotiation catalogs in China, the import channel is mainly completed through official registration and compliant cross-border distribution, ensuring that the source of drugs is formal, safe and traceable.

Reference materials:https://www.rinvoq.com/